†These authors contributed equally.
Background: There are increasing concerns towards the
transmission of extended spectrum-
Enterobacteriaceae resistance to extended-spectrum
This study focused on the bacterial distribution and drug resistance characteristics of ICU infections in obstetrics & gynecology departments. Furthermore, this study aimed to explore the epidemiology of pathogenic bacteria transmission and diffusion resistance by examining infectious cases at the ICU of a third-level hospital in Jilin, China between 2017 and 2019.
This study was conducted at a university-affiliated hospital, which is one of the largest hospitals in North-East China with approximately 2000 beds. This study conducted an analysis of retrospective data of Enterobacteriaceae-infected patients in three ICUs belonging to obstetrics & gynaecology settings. Two hundred and eighty-three patients who received treatment for cancer or tumor between June 2017 and June 2019 at the three ICUs were enrolled in this study. Patients with concurrent HAIs were classified according to the respiratory tract infections: pneumoniae, bloodstream infections such as catheter-related infections, urinary tract infections, surgical site infections, and other infections. For the most part, the pathogenic bacteria associated with an HAI were collected within 48 hours of hospitalization according to the local hospital criterion. Some samples were collected after 48 hours post-hospitalization. The specimens were mainly obtained from sputum or tracheal secretions, pus, blood, ascites, catheters, and drainage tubes. Multiple isolates from a single patient were excluded. The isolates from different infected sites of the same patient were also excluded. Ethical approval for collecting clinical samples was received by the institutional ethics committees of the participating hospital. Informed consent forms were reviewed and signed by all participants before sample collection.
E. coli and E. cloacae isolates were identified by using the Vitek 2 Compact System with GN and ASTGN13 cards (bioMérieux, Marcy l’Etoile, France). Susceptibility to a panel of 17 antimicrobial agents was assessed by using the broth microdilution method according to the recommendations by the Clinical and Laboratory Standards Institute (CLSI, 2012) [8]. The following antibiotics (AB Biodisk, Solna, Sweden) were tested: ampicillin, cefazolin, cefuroxime, ceftazidime, ceftriaxone, cefepime, levofloxacin, netilmicin, aztreonam, ciprofloxacin, amikacin, gentamicin, imipenem, meropenem, ampicillin/tazobactam, piperacillin/tazobactam and compound sulfamethoxazole.
E. coli ATTCC 25922 was the susceptible control strain, and K. pneumoniae 700603 and E. cloacae ATCC 13047 were the ESBL-positive control strains. K. pneumoniae A1500 was the carbapenemase-positive control strains.
Double-disk synergy test (DDST) was performed to screen for ESBLs and combined
with the EDTA-disc synergy to detect carbapenemase. Suspected ESBL-producing
strains were screened using cefotaxime (Oxoid, Basingstoke, UK) (30
A single colony was selected from the passage medium and incubated overnight at
37
The primer sequences were P1-ATGTAAGCTCCTGGGGATTCAC and P2-AAGTAAGTGACTGGGGTGAGCG.
The system contained 2
Differences in drug resistance rates of non-ESBL-producing and ESBL-producing
strains were tested by Chi-square test. All drug resistant data were analyzed
using SPSS version 13.0 (IBM Corp., Armonk, NY, USA). Analyses with a value of P
From June 2017 to June 2019, a total of 283 patients from three ICUs were enrolled in this study to estimate the quantity and types of infections present in this population. These patients received treatment or surgery for cancer or tumor at a median age of 63 years. Of the 283 samples, 104 were classified as E. coli and 103 as E. cloacae by the VITEK GNI system. The remaining samples were classified as other Enterobacteriaceae and non-Enterobacteriaceae, which were not included in this study (data not shown).
The clinical distribution of the specimens was mainly composed of sputum or tracheal secretions (n = 179, 63.3%), followed by skin and purulent infections (n = 33, 11.5%), blood (n = 43, 15.2%), ascites (n = 20, 7.1%), and catheters and drainage tubes (n = 8, 2.8%).
Resistance frequencies of ESBL-producing E. coli and E. cloacae isolates based on CLSI microdilution demonstrated that 67 (64.4%) strains of E. coli and 46 (44.7%) strains of E. cloacae isolates were ESBL-positive. No isolates were resistant to carbapenem.
Resistance rates of ESBL-producing E. coli and E. cloacae isolates were 95.5% and 91.3% for ampicillin, respectively; 80.6% and 76.1% for ampicillin/tazobactam; 88.1% and 28.3% for ciprofloxacin; 89.6% and 15.2% for levofloxacin; 34.3% and 45.7% for netilmicin; 82.1% and 41.3% for compound sulfamethoxazole; 20.9% and 43.5% for amikacin; 58.2% and 37.0% for gentamicin; and 20.9% and 69.6% for piperacillin/tazobactam. All of ESBL-producing isolates were 100% resistant to cefazolin, cefuroxime, ceftazidime, ceftriaxone, cefepime, and aztreonam. The susceptibilities of isolates to imipenem and meropenem were 100%.
The susceptibilities of non-ESBL-positive E. coli and E. cloacae isolates were 89.2% and 91.3% to ampicillin, respectively; 97.3% and 96.5% to ampicillin/tazobactam; 94.6% and 94.7% to cefazolin; 89.2% and 96.5% to cefuroxime; 97.3% and 98.3% to ceftazidime; 97.3% and 98.3% to ceftriaxone; 91.9% and 92.3% to cefepime; 89.2% and 100.0% to aztreonam; 32.4% and 68.4% to ciprofloxacin; 37.8% and 91.2% to levofloxacin; 70.3% and 56.1% to netilmicin; 43.2% and 61.4% to compound sulfamethoxazole; 62.2% and 71.9% to amikacin; 43.2% and 68.4% to gentamicin; and 97.3% and 93.0% to piperacillin/tazobactam. The susceptibilities to imipenem and meropenem were the only ones at 100%. The resistance rates to different antibiotics between ESBL-positive and non-ESBL-positive isolates are summarized in Tables 1 and 2.
Antimicrobiol agents | ESBL positive (n = 67) | ESBL negative (n = 37) | X |
P value | ||
R (%)* | S (%) | R (%) | S (%) | |||
Ampicillin | 64 (95.5) | 3 (4.5) | 4 (10.8) | 33 (89.2) | 4.42 | |
Ampicillin/azobactam | 54 (80.6) | 13 (19.4) | 1 (2.7) | 36 (97.3) | 5.01 | |
Cefazolin | 67 (100.0) | 0 (0.0) | 2 (5.4) | 35 (94.6) | 130.67 | |
Cefuroxime | 67 (100.0) | 0 (0.0) | 4 (10.8) | 33 (89.2) | 169.60 | |
Ceftazidime | 67 (100.0) | 0 (0.0) | 1 (2.7) | 36 (97.3) | 24.34 | |
Ceftriaxone | 67 (100.0) | 0 (0.0) | 3 (8.1) | 34 (91.9) | 83.79 | |
Cefepime | 67 (100.0) | 0 (0.0) | 3 (8.1) | 34 (91.9) | 19.51 | |
Aztreonam | 67 (100.0) | 0 (0.0) | 4 (10.8) | 33 (89.2) | 88.48 | |
Ciprofloxacin | 59 (88.1) | 8 (11.9) | 25 (67.6) | 12 (32.4) | 3.31 | |
Gentamicin | 39 (58.2) | 28 (41.8) | 21 (56.8) | 16 (43.2) | 3.80 | |
Imipenem | 0 (0.0) | 67 (100.0) | 0 (0.0) | 37 (100.0) | 2.01 | |
Meropenem | 0 (0.0) | 67 (100.0) | 0 (0.0) | 37 (100.0) | 0 | 0 |
Levofloxacin | 60 (89.6) | 7 (10.5) | 23 (62.2) | 14 (37.8) | 4.69 | |
Netilmicin | 23 (34.3) | 44 (65.7) | 11 (29.7) | 26 (70.3) | 4.91 | |
Compound sulfamethoxazole | 55 (82.1) | 12 (17.9) | 21 (56.8) | 16 (43.2) | 61.68 | |
Piperacillin/tazobactam | 14 (20.9) | 53 (79.1) | 1 (2.7) | 36 (97.3) | 4.54 | |
Amikacin | 20 (29.9) | 47 (70.2) | 14 (37.8) | 23 (62.2) | 4.74 | |
Note: *P |
Antimicrobiol agents | ESBL positive (n = 46) | ESBL negative (n = 57) | X |
P value | ||
R (%)* | S (%) | R (%) | S (%) | |||
Ampicillin | 42 (91.3) | 4 (8.7) | 4 (7.0) | 53 (93.0) | 4.42 | |
Ampicillin/azobactam | 35 (76.1) | 11 (23.9) | 2 (3.5) | 55 (96.5) | 4.52 | |
Cefazolin | 46 (100.0) | 0 (0.0) | 3 (5.3) | 54 (94.7) | 130.67 | |
Cefuroxime | 46 (100.0) | 0 (0.0) | 2 (3.5) | 55 (96.5) | 169.60 | |
Ceftazidime | 46 (100.0) | 0 (0.0) | 1 (1.8) | 56 (98.3) | 24.34 | |
Ceftriaxone | 46 (100.0) | 0 (0.0) | 4 (7.0) | 53 (93.0) | 83.79 | |
Cefepime | 46 (100.0) | 0 (0.0) | 2 (3.5) | 55 (96.5) | 19.51 | |
Aztreonam | 46 (100.0) | 0 (0.0) | 0 (0.0) | 57 (100.0) | 88.48 | |
Ciprofloxacin | 13 (28.3) | 33 (71.7) | 18 (31.6) | 39 (68.4) | 3.31 | |
Gentamicin | 17 (37) | 29 (63.0 | 20 (35.1) | 37 (64.9) | 3.80 | |
Imipenem | 0 (0.0) | 46 (100.0) | 0 (0.0) | 57 (100.0) | 2.01 | |
Meropenem | 0 (0.0) | 46 (100.0) | 0 (0.0) | 57 (100.0) | 0 | 0 |
Levofloxacin | 7 (15.2) | 39 (84.8) | 5 (8.8) | 52 (91.2) | 4.69 | |
Netilmicin | 21 (45.7) | 25 (54.4) | 25 (43.9) | 32 (56.1) | 4.91 | |
Compound sulfamethoxazole | 19 (41.3) | 27 (50.7) | 22 (38.6) | 35 (61.4) | 61.68 | |
Piperacillin/tazobactam | 32 (69.6) | 14 (30.4) | 4 (7.0) | 53 (93.0) | 4.21 | |
Amikacin | 20 (43.5) | 26 (56.5) | 16 (28.1) | 41 (71.9) | 4.27 | |
Note: *P |
Next, this study investigated a local difference of antibiotic resistance
between ESBLs and non-EBSL strains. This study found a significant difference
between non-ESBL-producing strains and ESBL-producing strains (P
Isolate clonality analysis of all ESBL-producing strains was conducted by ERIC-PCR typing. One distinct ERIC profile was observed amongst 46 strains of ESBL-producing E. cloacae, showing that these isolates were similar to clones (Fig. 1). A representative of the same band was selected in 67 ESBL-producing E. coli isolates from different samples for dendrogram cluster analysis. This analysis revealed 11 distinct patterns with a similarity coefficient of 0.8, indicating that these isolates have similar origins. A clonal association was found between these strains: 54 (80.6%) originated from identical clones (Figs. 2 and 3), indicating that there is an outbreak at the study setting. Furthermore, the medical history of ICU patients with the same drug-resistant strains was similar. The majority of drug-resistant strains with identical clones infected the lower respiratory tract. Approximately 76% of ICU patients had a history of mechanical ventilation.
Representative gel showing banding profiles by ERIC-PCR analysis
in ESBLs-producing E. cloacae isolates.
Note:
M: DNA molecular weight; 1~13: ESBLs-producing E.
cloacae isolates from different samples in ICU.
1-2: strains isolated from pus; 3-4: strains isolated from urine; 5-6: strains
isolated from blood; 7: strains isolated from ascite; 8-9: strains isolated from
cathers and drainage tube; 11-13: strains isolated from sputum or tracheal
secretions.
ERIC, Enterobacterial repetitive intergenic consensus.
Representative gel showing banding profiles by ERIC-PCR analysis
in ESBLs-producing E. coli isolates.
Note:
M: DNA molecular weight; 1~13: ESBLs-producing E. coli
isolates from different samples in ICU.
1-2: strains isolated from pus; 3-4: strains isolated from urine; 5-6: strains
isolated from blood; 7: strains isolated from ascite; 8-9: strains isolated from
cathers and drainage tube; 11-13: strains isolated from sputum or tracheal
secretions; ERIC, Enterobacterial repetitive intergenic consensus.
Dendrogram from ERIC-PCR analysis in ESBLs-producing E.
coli isolates.
Note:
The scale bar showed the similarity values. Isolates were considered as the same
origins if their similarity coefficients were equal to or more over 0.8, whereas,
lower 0.8 is different origins.
ERIC, Enterobacterial repetitive intergenic consensus.
Antibacterial drugs have been administered extensively in health care for the treatment of disease, especially for critically ill patients in the ICU. However, the incidence of infections resistant to ESBL-producing Enterobacteriaceae has rapidly increased in recent years [10]. Research has documented many instances of outbreaks of HAIs in ICUs caused by ESBL-producing E. coli and E. cloacae[11].
This study collected samples from ICU patients and found that the prevalence of
E. coli and E. cloacae isolates among ESBL-producing
Enterobacteriaceaewas estimated at 64.4% and 44.7%,
respectively. These isolates were most common in respiratory tract and
skin infections. The results of this study indicated that female patients with a
tumor or cancer were likely to be infected by ESBL-producing
Enterobacteriaceae due to their immunological status or the excessive
use of
ESBL-producing strains of E. coli and E. cloacae isolates showed statistically higher resistance rates to cephalosporins than non-ESBL-producing strains. In contrast, there was no obvious difference in the resistance to ciprofloxacin between ESBL-producing and non-ESBL-producing strains. Comparing the sensitivity of cephalosporin antibiotics with sulbactam and tazobactam, drug resistance in ESBL-producing strains was much lower than cephalosporins alone. The findings of this study demonstrate that antibiotic resistance in E. coli and E. cloacae can be reduced if ESBL production is addressed. All ESBL-producing strains exhibited high resistance to cephalosporins, while at the same time showed high sensitivity to carbapenems. Because the northeast part of China is the coldest region in the country with the highest incidence of respiratory system diseases, overuse of antimicrobial drugs with the exception of carbapenems might explain why this study found a difference in antimicrobial agent susceptibility. Additionally, the findings showed that ESBL-producing bacteria were more resistant to aminoglycosides and levofloxacin than those with high resistance to cephalosporin antibiotics. Resistance to synthetic antibiotics such as sulfonamides was also lower than resistance to ampicillin.
The initial use of advanced cephalosporin antibiotics, especially the unreasonable use of third generation cephalosporins, marks the beginning of habitual therapy. Habitual therapy may cause health care providers to ignore the role of aminoglycosides and other antibacterial drugs that may contribute to resistance to drugs. ESBL-producing E. coli and E. cloacae isolates transiently colonize on the hands of hospital staff, increasing the likelihood of horizontal transmission between patients. ESBL-producing Enterobacteriaceae were frequently accompanied by resistance to an array of antibiotics. Studies have shown that multiple drug resistance mechanisms exist for E. coli and E. cloacae including mutations in Amp C enzymes and porin loss [19, 20]. However, the molecular mechanism of resistance was outside the scope of this study and future research may consider paying attention to this research priority.
Clinically, the common utilization of high-grade cephalosporin antibiotics for
the treatment of ICU patients with nosocomial infections alongside the
unreasonable use of third-generation cephalosporins may have caused the large
number of drug-resistant strains that were found in the current study [21, 22].
As a result, patients who are ineffectively treated with advanced cephalosporins
or
In the present investigation, both E. coli and E. cloacae were
highly sensitive to carbapenems. No significant difference in resistance
was found between ESBL-producing and non-ESBL-producing strains, indicating that
carbapenems could be used to treat ESBL-resistant strains. Carbapenems, which are
atypical
In the epidemiological analysis of nosocomial infections in the ICU, ERIC-PCR was used to identify isolates based on ERIC-PCR fingerprints. Since the introduction of the ERIC-PCR technique by Versalovic et al. in 1991, the technique has been critical for the epidemiological investigation of Gram-negative bacteria [28]. Results of ERIC-PCR performed in this study found 11 distinct profiles across ESBL-producing E. coli isolates, and one distinct profile across 46 strains of ESBL-producing E. cloacae. Overall, ERIC profiles demonstrated that there is an outbreak of nosocomial infection (ESBL-producing E. coli and E. cloacae) in the ICUs of the hospital.
Interestingly, this study found that all 46 ESBL-producing E. cloacae strains belonged to the same clonal type. However, there was variation in the antimicrobial profile for netilmicin, sulphamethaxazole, piperacillin/tazobactam, and amikacin. These four antibiotics were seldom used in the study hospital. It is possible that the encoding resistant genes for these antibiotics were primarily carried by mobile genetic elements, such as transposons and introns on a plasmid. Evidence from this study illustrated that plasmid mediating ESBLs might produce other resistant gene expressions, which may be associated with an increased use of antibiotics. Moreover, the E. cloacae complex encompasses several species comprising of 12 genetic clusters [29]. This study found significant variation in the four antimicrobial profiles among these isolates from ICU across different years of this study. This may be due to shifting or point mutations in these mobile genetic structures that may exert a pressure for selection [30, 31].
In order to control the production and spread of ESBLs, health care providers may consider careful and reasonable use of antibacterial drugs. For example, health care providers might consider limiting the empirical routine application of high-level antibiotics. Education and awareness surrounding the appropriate use of antibacterial drugs amongst health care workers and patients should be strengthened alongside improving and clarifying antibiotic use guidelines in pharmacies and hospital ICUs [32]. These measures could effectively mitigate or reduce the spread of infection of ESBLs bacteria. Overall, this study emphasizes the need for medical staff to use antimicrobial agents rationally [33].
This study has some limitations. First, genotypic or molecular data of all strains were not documented. Second, the molecular epidemiology of isolates was not included. Future research may consider focusing on genetic types and the mechanism of transmission.
The findings of this study indicate that the ESBL-producing E. coli and E. cloacae clones are circulating in the ICU at obstetrics & gynaecology departments and constitute a major source of infection at a large hospital in China. This study also found that carbapenems may be a reasonable choice in the treatment of ESBL-producing bacteria. In summary, there is a strong need for increased hospital-wide surveillance and the development of adequate infection prevention strategies.
CLSI, the Clinical and Laboratory Standards Institute; DDST, Double-disk synergy
test; E. cloacae, Enterobacter cloacae; E. coli, Escherichia coli; ERIC,
Enterobacterial repetitive intergenic consensus; ESBL, extended-spectrum
KC conceived, designed the experiments and wrote a draft manuscript. MCL and XYB analyzed, interpreted the results of the experiments and revised the manuscript. GLY and WPL performed the experiments. XYB collected the clinical data. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Ethical approval for collecting clinical samples was received by the institutional ethics committees of the participating hospital. Informed consent forms were reviewed and signed by all participants before samples collection (Ethical approval number: Protocol Number 2019-01-01).
We thank three anonymous reviewers for excellent criticism of the article.
The present project was a part of National Natural Science Foundation of China project (81402979), the Jilin Science and Technology Development Program (20140307008YY and 2014C33155); the Health and Family Planning Commission of Jilin Province (2018J098) also supported the project.
The authors declare no conflict of interest.